E2730

E2730 is a novel, selective, uncompetitive inhibitor of gamma-aminobutyric acid (GABA) transporter 1 (GAT1), developed as an orally available small molecule for the treatment of epilepsy and drug-resistant seizures. Its mechanism of action involves selectively inhibiting GAT1-mediated GABA uptake in a manner that is positively correlated with environmental or synaptic GABA levels. This means E2730 preferentially increases extracellular GABA concentrations under conditions of heightened synaptic activity, such as during seizures, but has minimal effect under basal conditions. This selectivity contributes to a wide therapeutic window between anti-seizure efficacy and adverse effects like motor incoordination. E2730 has demonstrated broad anti-seizure activity in various animal models—including models for mesial temporal lobe epilepsy, Fragile X syndrome, and Dravet syndrome—without significant impact on motor coordination at effective doses[1][2][3][4][5][6].